Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Motif Bio notes statement from Amphion Innovations

21 Aug 2018 07:15

RNS Number : 3946Y
Motif Bio PLC
21 August 2018
 

Motif Bio plc

("Motif Bio" or the "Company")

 

Motif Bio notes statement from Amphion Innovations

 

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, notes the announcement made today via RNS by Amphion Innovations plc ("Amphion"), a substantial shareholder in the Company, relating to its sale of shares in Motif Bio to an institutional investor. Amphion now holds 8.51% of the issued share capital of Motif Bio. The full TR-1 disclosure is set out below.

 

For further information please contact:

 

Motif Bio plc

info@motifbio.com

Graham Lumsden (Chief Executive Officer)

 

 

 

 

 

Peel Hunt LLP (NOMAD & BROKER)

+ 44 (0)20 7418 8900

Dr Christopher Golden

 

Oliver Jackson

 

 

 

 

 

Northland Capital Partners Limited (BROKER)

+44 (0)20 3861 6625

David Hignell/Vadim Alexandre/Rob Rees

 

 

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0)20 7933 8780

Paul McManus/Helen Cresswell/Lianne Cawthorne

motifbio@walbrookpr.com

 

 

 

 

 

 

MC Services AG (EUROPEAN IR)

+49 (0) 89 210 2280

Raimund Gabriel

raimund.gabriel@mc-services.eu

 

 

 

 

Solebury Trout (U.S. IR)

+ 1 (646) 378-2963

Meggie Purcell

mpurcell@troutgroup.com

 

 

 

 

 

Russo Partners (U.S. PR)

+1 (858) 717-2310 or +1 (212) 845 4272

David Schull

david.schull@russopartnersllc.com

Travis Kruse, Ph.D.

travis.kruse@russopartnersllc.com

 

 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Motif Bio plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Amphion Innovations plc

City and country of registered office (if applicable)

 

4. Full name of shareholder(s) (if different from 3.)v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

August 20 2018

6. Date on which issuer notified (DD/MM/YYYY):

August 20 2018

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

8.51%

 

 

296,660,243

Position of previous notification (if

applicable)

9.53%

 

 

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB008BVVT4H71

25,254,611

 

8.51%

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

25,254,611

8.51%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

     

 

Place of completion

United Kingdom

Date of completion

August 20 2018

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLSELSIFFASEIA
Date   Source Headline
5th Nov 20071:39 pmRNSResult of EGM
31st Oct 20075:49 pmRNSTotal Voting Rights-Amendment
31st Oct 20072:18 pmRNSTotal Voting Rights
29th Oct 20077:00 amRNSWellGen Series C Financing
12th Oct 20077:30 amRNSIssue of Equity
12th Sep 20077:01 amRNSInterim Results
28th Aug 200710:25 amRNSNotice of Results
22nd Aug 20077:01 amRNSChange of Adviser
16th Aug 20079:31 amRNSRe: AIM Rule 26
14th Aug 20077:00 amRNSFundraising
30th Jul 20077:01 amRNSRe: Series C Financing
12th Jul 20079:19 amRNSPatent Awarded
2nd Jul 20077:01 amRNSPlacing
7th Jun 20077:01 amRNSAGM Statement
21st May 20071:52 pmRNSRe: Symposium
21st May 20071:00 pmBUSApplied Genomics Paves the Way for Improved Prevention, Diagnosis, and Treatment of Disease
14th May 20074:25 pmBUSAmphion Innovations plc (LSE: ''AMP'') Announces First Annual Science & Business Symposium ''Building Market Value from the World of Genetics''
30th Apr 200711:02 amRNSDirector Shareholdings
11th Apr 200711:31 amRNSResearch Update
5th Apr 20071:00 pmBUSAmphion Innovations Partner Company Motif Biosciences Closes $1m Financing
5th Apr 20079:24 amRNSDirector/PDMR Shareholding
5th Apr 20077:01 amRNSRe: Series C Financing
23rd Mar 20072:42 pmBUSPort of Barbados Selects AXCESS to Provide Security Systems for the Cricket World Cup 2007
23rd Mar 20077:01 amRNSRe: Cricket World Cup
15th Mar 20077:01 amRNSFinal Results
26th Feb 20074:44 pmRNSNotice of Results
9th Feb 20077:00 amRNSRe: Financing
16th Jan 20073:25 pmBUSAmphion Innovations, plc Announces Creation of a Gulf-based Joint Venture
16th Jan 20073:19 pmBUSAmphion Innovations, plc Offers Trading Update
16th Jan 20077:01 amRNSJoint Venture
16th Jan 20077:00 amRNSTrading Update
8th Jan 20074:28 pmBUSAmphion Innovations plc Announces Fundraising
8th Jan 20071:08 pmRNSFundraising - Replacement
8th Jan 20077:00 amRNSFundraising
27th Nov 20063:04 pmBUSAmphion Innovations plc Acquires 35% Stake in Manchester Molecular Diagnostic Spin-out Company
27th Nov 20067:00 amRNSAcquires Stake in Company
13th Nov 20062:58 pmBUSAmphion Innovations plc Partner Company Supertron Acquires Spin Systems
13th Nov 20067:01 amRNSAcquisition
7th Nov 200610:24 amRNSRe: Partner Company
2nd Nov 20064:36 pmRNSDirector/PDMR Shareholding
24th Oct 20069:03 amRNSDirector/PDMR Shareholding
14th Sep 20067:00 amRNSWellGen CEO
12th Sep 20067:00 amRNSChange of Adviser
7th Sep 20067:01 amRNSInterim Results
22nd Aug 20064:00 pmRNSFireStar Software, Inc
17th Aug 20067:01 amRNSAdditional Shares Placed
9th Aug 20061:43 pmRNSIssue of Equity
24th Jul 20067:02 amRNSSeries C Financing
12th Jun 20064:58 pmRNSResult of AGM
8th Jun 20067:03 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.